Pfizer (NYSE:PFE) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.15, MarketWatch Earnings reports. The company had revenue of $14.58 billion for the quarter, compared to analysts’ expectations of $13.41 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. Pfizer’s quarterly revenue was up 44.6% on a year-over-year basis. During the same period last year, the firm earned $0.80 earnings per share. Pfizer updated its FY 2021 guidance to 3.550-3.650 EPS and its FY21 guidance to $3.55-3.65 EPS.
Shares of Pfizer stock remained flat at $$39.83 during trading hours on Tuesday. The stock had a trading volume of 1,788,647 shares, compared to its average volume of 31,749,029. The firm has a 50-day simple moving average of $37.02 and a 200-day simple moving average of $36.78. Pfizer has a twelve month low of $31.61 and a twelve month high of $43.08. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $222.16 billion, a PE ratio of 25.61, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Thursday, May 6th. Pfizer’s payout ratio is currently 52.88%.
A hedge fund recently bought a new stake in Pfizer stock. OLD Mission Capital LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,918 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. 67.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Read More: Inverted Yield Curve
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.